Wells Fargo analyst Mohit Bansal raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Overweight rating on the shares. The firm says 2025 guide signals resilience despite strong IRA and FX headwinds, with HIV business holding steady. Wells is bullish as margin expansion accelerates, new launches provide strong growth prospects, and pipeline looks promising.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Balancing Strong HIV Franchise Performance with Cautious Outlook
- Gilead Sciences Reports Strong 2024 Financial Performance
- Gilead Sciences: Strong Financial Performance and Promising Future Prospects Justify Buy Rating
- Closing Bell Movers: Upstart jumps 24%, Lyft slip 9% on earnings
- Gilead reports Q4 adjusted EPS $1.90, consensus $1.70